Ubrogepant
Catalog No. A21670
Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine.
| Catalog Num | A21670 |
|---|---|
| M. Wt | 549.54 |
| Formula | C29H26F3N5O3 |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 1374248-77-7 |
| Synonyms | MK-1602, MK1602, MK 1602 |
| SMILES | O=C(C1=CN=C2C(C[C@@]3(C4=CC=CN=C4NC3=O)C2)=C1)N[C@@H]5C(N(CC(F)(F)F)[C@H](C)[C@H](C6=CC=CC=C6)C5)=O |
Ubrogepant (MK-1602) is a novel oral calcitonin gene-related peptide receptor (CGRP) antagonist in development for acute treatment of migraine.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 18.2 mL | 90.99 mL | 181.97 mL |
| 0.5 mM | 3.64 mL | 18.2 mL | 36.39 mL |
| 1 mM | 1.82 mL | 9.1 mL | 18.2 mL |
| 5 mM | 0.36 mL | 1.82 mL | 3.64 mL |
*The above data is based on the productmolecular weight 549.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: sales@adooq.com
ADOOQ 产品质量保证
We promise all products to perform as described.